Unveiling the Clinical Profiles for Patients With Asthma and Chronic Obstructive Pulmonary Disease Starting Single-inhaler Triple Therapy With Fluticasone Furoate/Umeclidinium/Vilanterol (FF/ UMEC/VI)

被引：0
|
作者：
Narendra, D. [1 ]
Baptist, A. P. [2 ]
Lee, L. [3 ]
Noorduyn, S. G. [4 ]
Liu, M. [5 ]
Igboekwe, E. E. [6 ]
Veeranki, P. [5 ]
Kahle-Wrobleski, K. [7 ]
Paczkowski, R. [3 ]
机构：
[1] Baylor Coll Med, Houston, TX USA
[2] Univ Michigan, Sch Med, Ann Arbor, MI USA
[3] GSK, Value Evidence & Outcomes, Collegeville, PA USA
[4] GSK, Global Value Evidence & Outcomes, Mississauga, ON, Canada
[5] Optum, Hlth Econ & Outcomes Res, Minneapolis, MN USA
[6] GSK, US Med Affairs, Raleigh, NC USA
[7] GSK, US Med Affairs, Collegeville, PA USA
来源：
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE | 2024年 / 209卷
关键词：
D O I：
暂无
中图分类号：
R4 [临床医学];
学科分类号：
1002 ; 100602 ;
摘要：
A2091
引用
收藏
页数：2
相关论文
共 50 条
  • [21] Real-World Study of Single-Inhaler Triple Therapy with Fluticasone Furoate/Umeclidinium/Vilanterol on Asthma Control in the US
    Bogart, Michael
    Germain, Guillaume
    Laliberte, Francois
    Mahendran, Malena
    Duh, Mei Sheng
    Dirocco, Kristi
    Noorduyn, Stephen G.
    Paczkowski, Rosirene
    Balkissoon, Ronald
    JOURNAL OF ASTHMA AND ALLERGY, 2023, 16 : 1309 - 1322
  • [22] Correction: Benefit of prompt initiation of single-inhaler fluticasone furoate, umeclidinium, and vilanterol (FF/UMEC/VI) in patients with COPD in England following an exacerbation: a retrospective cohort study
    Afisi S. Ismaila
    Kieran J. Rothnie
    Robert P. Wood
    Victoria L. Banks
    Lucinda J. Camidge
    Alexandrosz Czira
    Chris Compton
    Raj Sharma
    Shannon N. Millard
    Olivia Massey
    David M. G. Halpin
    Respiratory Research, 25
  • [23] Pharmacokinetic (PK) analysis of fluticasone furoate (FF), umeclidinium (UMEC) and vilanterol (VI) following triple therapy in healthy subjects
    Allen, A.
    Henderson, A.
    Gupta, A.
    Renaux, J.
    Brealey, N.
    EUROPEAN RESPIRATORY JOURNAL, 2014, 44
  • [24] BENEFIT-RISK PROFILES OF FLUTICASONE FUROATE/UMECLIDINIUM/VILANTEROL (FF/UMEC/VI) VS UMEC/VI IN PATIENTS WITH COPD: A MARKOV MODEL
    Bratton, Daniel
    Hartley, Benjamin
    Barnes, Neil
    Brusselle, Guy
    Compton, Christopher
    Corbridge, Thomas
    Dransfield, Mark
    Halpin, David
    Han, Meilan
    Jones, Christine Elaine
    Jones, Paul
    Lange, Peter
    Lipson, David
    Martinez, Fernando
    Papi, Alberto
    Roche, Nicolas
    Singh, Dave
    Wise, Robert
    CHEST, 2020, 158 (04) : 1666A - 1671A
  • [25] A single inhaler triple therapy fluticasone furoate/umeclidinium/vilanterol for the treatment of COPD
    Cazzola, Mario
    Rogliani, Paola
    Calzetta, Luigino
    Ora, Josuel
    Matera, Maria Gabriella
    EXPERT REVIEW OF CLINICAL PHARMACOLOGY, 2022, 15 (03) : 269 - 283
  • [26] Single-Inhaler Triple Therapy Fluticasone Furoate/Umeclidinium/Vilanterol Improves Lung Function and Symptoms Compared with Tiotropium Monotherapy in Patients with Symptomatic Chronic Obstructive Pulmonary Disease at Risk of Exacerbations
    Obeid, D.
    Bansal, S.
    Brown, N.
    Compton, C.
    Corbridge, T. C.
    Dorais, K.
    Erb, D.
    Harvey, C.
    Kaisermann, M. C.
    Kaye, M.
    Lipson, D. A.
    Martin, N.
    Zhu, C. Q.
    Papi, A.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2020, 201
  • [27] Effect of Recent Exacerbation History on the Efficacy of Once-Daily Single-Inhaler Fluticasone Furoate/Umeclidinium/Vilanterol Triple Therapy in Patients with Chronic Obstructive Pulmonary Disease in the FULFIL Trial
    Panettieri, Reynold A., Jr.
    Camargo, Carlos A., Jr.
    Cheema, Tariq
    Bayadi, Sherif G. El
    Fiel, Stanley
    Vila, Tania M.
    Jain, Renu G.
    Midwinter, Dawn
    Thomashow, Byron
    Ludwig-Sengpiel, Andrea
    Lipson, David A.
    INTERNATIONAL JOURNAL OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE, 2022, 17 : 2043 - 2052
  • [28] Pharmacokinetic (PK) analysis of fluticasone furoate (FF), umeclidinium (UMEC) and vilanterol (VI) following triple therapy at two UMEC doses in healthy subjects
    Henderson, A.
    Allen, A.
    Gupta, A.
    Renaux, J.
    Brealey, N.
    EUROPEAN RESPIRATORY JOURNAL, 2014, 44
  • [29] The IMPACT Trial: Single Inhaler Triple Therapy Fluticasone Furoate/Umeclidinium/Vilanterol Versus Fluticasone Furoate/Vilanterol and Umeclidinium/Vilanterol in Patients with COPD: Results on Cardiovascular Safety
    Lipson, D. A.
    Criner, G.
    Dransfield, M. T.
    Halpin, D. M. G.
    Han, M. K.
    Jones, C. E.
    Kilbride, S.
    Lange, P.
    Lomas, D. A.
    Martinez, F. J.
    Pascoe, S.
    Singh, D.
    Wise, R. A.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2019, 199
  • [30] REAL-WORLD ADHERENCE TO SINGLE-INHALER FLUTICASONE FUROATE/UMECLIDINIUM/VILANTEROL VERSUS MULTIPLE-INHALER TRIPLE THERAPY AMONG ASTHMA PATIENTS IN THE US
    Averell, C.
    Germain, G.
    Laliberte, F.
    MacKnight, S.
    Jung, Y.
    Duh, M. S.
    Abbott, C.
    VALUE IN HEALTH, 2021, 24 : S13 - S13
12345